JP2021502573A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021502573A5 JP2021502573A5 JP2020544567A JP2020544567A JP2021502573A5 JP 2021502573 A5 JP2021502573 A5 JP 2021502573A5 JP 2020544567 A JP2020544567 A JP 2020544567A JP 2020544567 A JP2020544567 A JP 2020544567A JP 2021502573 A5 JP2021502573 A5 JP 2021502573A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- steps
- peripheral
- protein
- peripheral arterial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 14
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 9
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 9
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 claims 7
- 230000002093 peripheral effect Effects 0.000 claims 7
- 108010082548 Chemokine CCL11 Proteins 0.000 claims 5
- 102100023688 Eotaxin Human genes 0.000 claims 5
- 206010020772 Hypertension Diseases 0.000 claims 5
- 102000013264 Interleukin-23 Human genes 0.000 claims 5
- 108010065637 Interleukin-23 Proteins 0.000 claims 5
- 102000016776 Midkine Human genes 0.000 claims 5
- 108010092801 Midkine Proteins 0.000 claims 5
- 229940124829 interleukin-23 Drugs 0.000 claims 5
- 102000005741 Metalloproteases Human genes 0.000 claims 4
- 108010006035 Metalloproteases Proteins 0.000 claims 4
- 239000012472 biological sample Substances 0.000 claims 4
- 239000011159 matrix material Substances 0.000 claims 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Chemical compound OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 4
- 102000009088 Angiopoietin-1 Human genes 0.000 claims 3
- 108010048154 Angiopoietin-1 Proteins 0.000 claims 3
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims 3
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims 3
- 229940028334 follicle stimulating hormone Drugs 0.000 claims 3
- 208000017169 kidney disease Diseases 0.000 claims 3
- 238000007888 peripheral angioplasty Methods 0.000 claims 3
- 239000012474 protein marker Substances 0.000 claims 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims 2
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims 2
- 101710155859 C-C motif chemokine 5 Proteins 0.000 claims 2
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims 2
- 102000006818 Cell Adhesion Molecule-1 Human genes 0.000 claims 2
- 108010072135 Cell Adhesion Molecule-1 Proteins 0.000 claims 2
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 claims 2
- 102000006395 Globulins Human genes 0.000 claims 2
- 108010044091 Globulins Proteins 0.000 claims 2
- 102000003886 Glycoproteins Human genes 0.000 claims 2
- 108090000288 Glycoproteins Proteins 0.000 claims 2
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims 2
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 claims 2
- 102000008070 Interferon-gamma Human genes 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 claims 2
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims 2
- 102000004890 Interleukin-8 Human genes 0.000 claims 2
- 108090001007 Interleukin-8 Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102000004264 Osteopontin Human genes 0.000 claims 2
- 108010081689 Osteopontin Proteins 0.000 claims 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims 2
- 101710188053 Protein D Proteins 0.000 claims 2
- 101710132893 Resolvase Proteins 0.000 claims 2
- 102000058242 S100A12 Human genes 0.000 claims 2
- 108700016890 S100A12 Proteins 0.000 claims 2
- 102000012005 alpha-2-HS-Glycoprotein Human genes 0.000 claims 2
- 108010075843 alpha-2-HS-Glycoprotein Proteins 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- -1 cellophyltransferase Proteins 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000001605 fetal effect Effects 0.000 claims 2
- 230000003325 follicular Effects 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229960003130 interferon gamma Drugs 0.000 claims 2
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 claims 2
- 229940096397 interleukin-8 Drugs 0.000 claims 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims 2
- 229940066294 lung surfactant Drugs 0.000 claims 2
- 239000003580 lung surfactant Substances 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 239000002243 precursor Substances 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 230000000250 revascularization Effects 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 230000002485 urinary effect Effects 0.000 claims 2
- 238000009007 Diagnostic Kit Methods 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 238000002583 angiography Methods 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 102000008373 cell-cell adhesion mediator activity proteins Human genes 0.000 claims 1
- 108040002566 cell-cell adhesion mediator activity proteins Proteins 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000001647 drug administration Methods 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 238000011002 quantification Methods 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002604 ultrasonography Methods 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762580916P | 2017-11-02 | 2017-11-02 | |
| US62/580,916 | 2017-11-02 | ||
| PCT/US2018/059080 WO2019090166A1 (en) | 2017-11-02 | 2018-11-02 | Diagnostic and prognostic methods for peripheral arterial diseases, aortic stenosis, and outcomes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021502573A JP2021502573A (ja) | 2021-01-28 |
| JP2021502573A5 true JP2021502573A5 (enExample) | 2021-12-09 |
| JP7372251B2 JP7372251B2 (ja) | 2023-10-31 |
Family
ID=66332348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544567A Active JP7372251B2 (ja) | 2017-11-02 | 2018-11-02 | 末梢動脈疾患、大動脈弁狭窄症についての診断および予後の方法、ならびにアウトカム |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220229071A1 (enExample) |
| EP (1) | EP3704491A4 (enExample) |
| JP (1) | JP7372251B2 (enExample) |
| CA (1) | CA3081752A1 (enExample) |
| WO (1) | WO2019090166A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11657921B2 (en) | 2019-09-18 | 2023-05-23 | Tempus Labs, Inc. | Artificial intelligence based cardiac event predictor systems and methods |
| CN111803064A (zh) * | 2020-06-22 | 2020-10-23 | 燕山大学 | 基于eeg和血清炎症因子分析脑损伤标志物的方法 |
| US20230358762A1 (en) * | 2020-09-16 | 2023-11-09 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Diagnostic methods for kawasaki disease |
| US20230349926A1 (en) * | 2020-09-22 | 2023-11-02 | Ohio State Innovation Foundation | Methods, compositions, and kits for detecting and measuring endothelial injury in normal and diseased human central nervous system (cns) |
| WO2022251748A1 (en) * | 2021-05-28 | 2022-12-01 | Tempus Labs, Inc. | Artificial intelligence based cardiac event predictor systems and methods |
| CN117642630A (zh) * | 2021-06-01 | 2024-03-01 | 香港大学 | 用于非酒精性脂肪肝病的纤维化生物标志物 |
| US20240266008A1 (en) * | 2023-02-01 | 2024-08-08 | Unlearn.AI, Inc. | Systems and Methods for Designing Augmented Randomized Trials |
| CN115938590B (zh) * | 2023-02-09 | 2023-05-02 | 四川大学华西医院 | 结直肠癌术后lars预测模型的构建方法及预测系统 |
| KR20250031367A (ko) * | 2023-08-28 | 2025-03-07 | 고려대학교 산학협력단 | 동맥경화증 진단용 엑소좀 유래 바이오 마커 |
| CN117031042B (zh) * | 2023-09-05 | 2024-05-31 | 上海爱谱蒂康生物科技有限公司 | 用于筛查诊断先天性心脏病胎儿的生物标志物及其应用 |
| CN117393171B (zh) * | 2023-12-11 | 2024-02-20 | 四川大学华西医院 | 直肠癌术后lars发展轨迹预测模型构建方法及系统 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1756554A4 (en) | 2004-06-03 | 2009-04-29 | Vermillion Inc | BIOMARKERS FOR PERIPHERAL ARTERY DISEASE |
| US20100331200A1 (en) * | 2006-03-31 | 2010-12-30 | Gordon Neal F | Post translational modification pattern analysis |
| WO2008057806A1 (en) | 2006-11-01 | 2008-05-15 | Vermillion, Inc. | A panel of biomarkers for peripheral arterial disease |
| US8227201B2 (en) | 2007-06-27 | 2012-07-24 | Board Of Trustees Of The Leland Stanford Junior University | BETA2-microglobulin and C reactive protein (CRP) as biomarkers for peripheral artery disease |
| US20110065593A1 (en) * | 2009-08-07 | 2011-03-17 | Rules-Based Medicine, Inc. | Computer Methods and Devices for Detecting Kidney Damage |
| US20110144914A1 (en) * | 2009-12-09 | 2011-06-16 | Doug Harrington | Biomarker assay for diagnosis and classification of cardiovascular disease |
| CA2953789A1 (en) * | 2013-07-12 | 2015-01-15 | Emory University | Diagnostic assay to predict cardiovascular risk |
| JP6788879B2 (ja) | 2015-06-24 | 2020-11-25 | 国立研究開発法人理化学研究所 | 末梢動脈疾患検査方法及び検査用試薬 |
| CN108700596A (zh) * | 2016-02-01 | 2018-10-23 | 普雷西奥公司 | 用于心血管疾病和事件的诊断和预后方法 |
-
2018
- 2018-11-02 CA CA3081752A patent/CA3081752A1/en active Pending
- 2018-11-02 EP EP18872375.3A patent/EP3704491A4/en not_active Withdrawn
- 2018-11-02 WO PCT/US2018/059080 patent/WO2019090166A1/en not_active Ceased
- 2018-11-02 JP JP2020544567A patent/JP7372251B2/ja active Active
- 2018-11-02 US US16/760,889 patent/US20220229071A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021502573A5 (enExample) | ||
| Hoeper et al. | Definitions and diagnosis of pulmonary hypertension | |
| Khoury et al. | Cardiac and vascular target organ damage in pediatric hypertension | |
| JP2019507354A5 (enExample) | ||
| Samuel et al. | Diastolic dysfunction in women with ischemia and no obstructive coronary artery disease: mechanistic insight from magnetic resonance imaging | |
| Hamamoto et al. | A new pre-test probability score for diagnosis of deep vein thrombosis in patients before surgery | |
| Gafane-Matemane et al. | Associations of central and peripheral blood pressure with the renin-angiotensin-aldosterone system in healthy young adults: the African-PREDICT study | |
| Arican et al. | The role of right ventricular volumes and inferior vena cava diameters in the evaluation of volume status before colonoscopy | |
| Justin et al. | Performance of hepatic artery velocity in evaluation of causes of markedly elevated liver tests | |
| Rakhimova | Impared endothelial dysfunction in covid-19: an overview of evidence, biomarkers in patients with ankylosing spondylitis | |
| Gombert et al. | Assessment of neurone-specific enolase, glial fibrillary acidic protein and S100 B as spinal cord ischemia biomarkers in patients undergoing open and endovascular complex aortic surgery: a single-center experience | |
| Lin et al. | Association of echocardiographic parameters with all-cause and cardiovascular mortality in patients with type 2 diabetes | |
| Lala et al. | Frailty measures of patient-reported activity and fatigue may predict 1-year outcomes in ambulatory advanced heart failure: a report from the REVIVAL registry | |
| Kellermair et al. | High-molecular-weight von Willebrand Factor multimer ratio: a novel biomarker for low-flow, low-gradient aortic stenosis subclassification | |
| Shibata et al. | Six-month trajectory of phase angle after cardiovascular surgery and associated factors of the recovery during cardiac rehabilitation: A retrospective cohort study | |
| Ghafori et al. | The relationship between renal arterial resistive index (RRI) and renal outcomes in patients with resistant hypertension | |
| Brietzke et al. | Predictors of skeletal muscle index for patients treated with hemodialysis | |
| Akhmadalieva | Diagnosis of the degree of liver fibrosis in patients with chronic hepatitis and cirrhosis of the liver | |
| Wernhart et al. | Incidence of cardiovascular risk factors and exercise phenotyping in cardiomyopathies: One size does not fit all | |
| Bissessor et al. | The role of natriuretic peptides in patients with chronic complex (mixed or multiple) heart valve disease | |
| Volkers et al. | P544 Point-of-care finger prick test for C-reactive protein, infliximab and adalimumab serum concentrations | |
| Arslan et al. | Predictive Value of Renal Resistive Index in Occult Hemorrhage in Hemodynamically Stable Polytrauma Patients in Emergency Department | |
| de Carvalho et al. | Early detection of acute kidney injury in critically ill children: Predictive value of renal arterial Doppler assessment | |
| Abrignani | Searching Novel Approaches to Cardiovascular Risk: Hypertensive Disorders of Pregnancy | |
| Hayat et al. | Evaluation of the Renin-Angiotensin Pathway in Paediatric Hypertension |